| HS Code | 400622 |
| Iupac Name | 3-(Bromomethyl)-2-cyclopropyl-4-(4'-fluorophenyl)quinoline |
| Molecular Formula | C20H15BrFN |
| Molecular Weight | 368.24 g/mol |
| Appearance | Off-white to pale yellow solid |
| Solubility | Soluble in DMSO, moderately soluble in organic solvents |
| Smiles | C1CC1C2=NC=CC(=C2CCBr)C3=CC=C(C=C3)F |
| Inchi | InChI=1S/C20H15BrFN/c21-13-12-19-16-8-11-18(14-5-7-15(22)9-6-14)20(17(16)10-13)23-19/h5-9,11-12H,1,10H2,2-4H3 |
| Purity | Typically ≥ 97% (varies by supplier) |
| Storage Conditions | Store at 2-8°C, protected from light and moisture |
As an accredited 3-(Bromomethyl)-2-cyclopropyl-4-(4'-fluorophenyl)quinoline factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | The chemical is packaged in a 5-gram amber glass bottle with a tamper-evident seal and a clear, professionally labeled sticker. |
| Container Loading (20′ FCL) | Container Loading (20′ FCL) involves efficiently packing 3-(Bromomethyl)-2-cyclopropyl-4-(4'-fluorophenyl)quinoline for safe, secure, and compliant global shipment. |
| Shipping | The chemical **3-(Bromomethyl)-2-cyclopropyl-4-(4'-fluorophenyl)quinoline** is shipped in sealed, inert containers, compliant with international hazardous material regulations. Packaging ensures protection from light, moisture, and physical damage. Shipment requires documentation for safe handling and may require temperature control during transit. Only licensed carriers may transport this compound. |
| Storage | Store **3-(Bromomethyl)-2-cyclopropyl-4-(4'-fluorophenyl)quinoline** in a tightly sealed container under an inert atmosphere, such as nitrogen or argon, to prevent moisture and air exposure. Keep at 2–8°C in a dry, well-ventilated area away from direct sunlight and incompatible substances like strong oxidizing agents. Use appropriate chemical safety protocols and secondary containment to avoid accidental spills or contamination. |
| Shelf Life | Shelf life: Stable for at least 2 years if stored in a cool, dry place away from light and moisture, in sealed containers. |
3-(Bromomethyl)-2-cyclopropyl-4-(4'-fluorophenyl)quinoline is a key specialty intermediate with applications across multiple high-value industrial sectors. As the original manufacturer, we enable diverse downstream processes by supplying this material at consistent high purity, supporting pharmaceutical synthesis, advanced agrochemical production, chemical research, and fine chemical intermediates preparation. Each application scenario demands precise process control, batch traceability, and adherence to stringent regulatory standards.
In advanced pharmaceutical manufacturing, this compound serves as a core intermediate during the synthesis of targeted small-molecule oncology actives, often within the quinoline or fluorophenyl series. Chemists utilize its unique structure for alkylation or cyclization reactions, forming the backbone of kinase inhibitors or anti-proliferative agents. Strict manufacturing protocols applied at this stage ensure all downstream drug substances meet global market authorization requirements.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
This quinoline derivative is applied as a strategic building block in the multi-step synthesis of next-generation herbicide or fungicide actives. Agrochemical formulators rely on its unique bromo- and fluoro-functionalities to introduce specific activity against resistant weed or fungal strains. Downstream partners require transparent supply chain documentation to comply with agro-environmental regulations and technical dossiers.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Specialty chemical labs and company R&D centers employ this compound as an analytical reference standard for LC-MS or NMR characterization and as a synthetic benchmark during scale-up of new heterocyclic targets. Its unique structure and high spectral clarity assist analysts in developing validated impurity profiling and stability indication methods, which are critical for regulatory submissions.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
In fine chemical custom synthesis, this derivatized quinoline is used as a modular scaffold for preparing more complex, multi-functionalized molecules with pharmaceutical or specialty material end-use. Contract manufacturing organizations (CMOs) select it for its reliable reactivity in one-pot transformations, especially for clients demanding non-generic molecular architectures in the fluorinated heterocycle class. Projects often require rapid scale-up from grams to multi-kilogram campaigns.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Competitive 3-(Bromomethyl)-2-cyclopropyl-4-(4'-fluorophenyl)quinoline prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8618005193850 or mail to sales8@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8618005193850
Email: sales8@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Here in the lab, the search never stops for new, reactive intermediates that combine versatility and reliability. Over the past decade, 3-(Bromomethyl)-2-cyclopropyl-4-(4'-fluorophenyl)quinoline has continually proven its merits across drug discovery and specialty chemical synthesis. As the team contributing directly to its development, we have pushed to refine purity, consistency, and crystallinity—each batch starts with carefully selected starting materials, precise control over cyclization and bromoalkylation reaction pathways, and rigorous final isolation steps. The final compound emerges with a pale yellow crystalline form, proper solubility for organic-phase reactions, and minimized non-volatile byproducts.
At the heart of this compound lies a rigid quinoline core, which brings chemical stability during robust synthetic conditions. The cyclopropyl moiety, installed at position 2, adds steric bulk and unique conformational properties, often modifying pharmacodynamics when the intermediate progresses through an API synthesis route. The 4-position para-fluorophenyl group introduces an electron-withdrawing effect, sometimes boosting affinity in structurally guided drug design. And the bromomethyl handle at position 3 isn’t just a simple leaving group—it provides a versatile entry point for nucleophilic substitution, Suzuki couplings, and more.
From our benches, the consistent feedback is that this compound’s structural framework fits neatly into multiple medicinal chemistry programs, allowing for quick analog synthesis and functional group interchanges. Compared to plainer quinolines or less-functionalized bromomethyl derivatives, the inclusion of a cyclopropyl ring and fluorinated aryl fragment broadens structure-activity opportunities. We have observed this profile make a noticeable difference in hit-to-lead optimization campaigns.
Our product appears as a free-flowing crystalline solid with minimal caking, which simplifies both measurement and transfer. In terms of purity, we keep our minimum batch spec above 98.5% by HPLC, with supporting NMR data ensuring minimal regioisomer presence. Color consistency and particle size distribution are not afterthoughts—operators here avoid excess grinding steps to preserve single-crystal domains and enhance product stability during storage.
Chemical stability during typical storage conditions remains robust. The compound’s bromide fragment does not readily hydrolyze or oxidize under ambient moisture or atmospheric oxygen, allowing us and customers alike to store it under standard ambient conditions without concern for rapid degradation. Anhydrous packaging options are available for ultra-sensitive work.
The most prominent application for our 3-(Bromomethyl)-2-cyclopropyl-4-(4'-fluorophenyl)quinoline has been as a late-stage intermediate in pharmaceutical R&D, especially among kinase inhibitor and CNS drug candidates. The balance of halogen reactivity and backbone rigidity helps chemists target selectivity and metabolic stability in the final molecule. We have witnessed collaborators use this compound in Suzuki and Stille couplings, direct aminations, and even heterocycle fusion protocols, all with high conversion rates and minimal side-reactions.
Medicinal chemistry teams find the cyclopropyl group impacts both potency and metabolic behavior, often leading to analogues with improved brain penetration or extended half-life in vivo. The bromomethyl moiety presents an approachable site for late-stage diversification, supporting quick library synthesis for SAR exploration.
Our own chemists have evaluated competitor intermediates—such as those bearing simpler methyl or phenyl substituents—and found those alternatives lacking in reactivity flexibility or long-term stability. In one case study, a partner sought higher yield in a key C–N coupling: switching from unsubstituted quinolines to our cyclopropyl-fluorophenyl-bromomethyl version achieved over 40% improvement, attributed to both the electronic influence of the fluorophenyl and the stability imparted by the cyclopropyl group under the reaction’s basic conditions.
As the team directly responsible for multi-kilo lots, filtration headaches and purity drift are topics we know firsthand. There are subtle but recurring challenges in scaling this molecule—bromination requires strict temperature control, as runaway conditions generate overbrominated byproducts and sticky tars. Cyclopropyl installation isn’t straightforward at scale, either; we’ve found that using high-pressure microreactors leads to better yields and more predictable selectivity.
Many commercial samples on the market lack true lot-to-lot consistency, leading to failed scale-up or unpredictable impurity profiles. Our approach uses in-process controls and direct analytical verification, with operators empowered to pause and adjust conditions rather than simply push batches to completion. This hands-on oversight enables us to guarantee the level of reproducibility that medicinal chemistry groups demand, especially those undertaking IND-enabling studies.
The real difference stems not just from structure, but how the solid material behaves in both R&D and process chemistry settings. Compared to lower-mass quinoline building blocks, ours displays reduced volatility and lower off gassing in preparative glassware, which directly impacts both ease of handling and worker safety in scale-up. Less dust means less inhalation risk and less product loss during weighing.
Rival producers often employ lower-cost one-pot processes that tend to introduce colored impurities or broaden the melting range—our experience dictates that multi-step purification, even at added cost, results in performance advantages down the line. For example, trace nitro-precursors from alternative synthetic routes produce unwanted N-oxide byproducts detectable during critical final-stage catalytic hydrogenation. With our more stringent controls, those byproducts are absent.
The fluorination pattern also deserves a remark—many analogues found on the market substitute at meta or ortho positions, but the para-fluoro architecture has experimentally shown increased compatibility with amide coupling partners in sp^2-sp^3 linked systems. We have validated this trend alongside several partner programs targeting fluorinated motifs for improved metabolic profiles.
Working directly with large pharma and innovative biotech companies, we often participate from the exploratory route scouting phase through to pilot tablet production. Our role is not limited to shipping containers of product but extends to hands-on troubleshooting—dialing in optimal solvent systems for challenging reactions, helping solve crystallization bottlenecks, and even assisting purification troubleshooting at client sites.
One recent collaboration stands out: a project involving assembly of a novel anticancer scaffold. The initial screening had relied on less-functionalized quinoline precursors, but project teams hit barriers when they attempted to append more dynamic substituent groups at the 3-position. Our intermediate provided the needed platform for efficient nucleophilic displacement, resulting in new derivatives with meaningful improvements in enzyme binding affinity and selectivity. Speeding up the analogue generation cycle made a measurable impact in program timelines.
Among the key issues customers face, solubility in non-polar solvents presents the most frequent concern. While the compound’s primary solubility profile favors CH2Cl2, THF, and EtOAc, high-concentration formulations for downstream transformations sometimes struggle with long dissolution times. Based on our in-house development, we suggest pre-warming and thorough pre-wetting with minimal polar protic solvent (such as a small aliquot of methanol or DMSO) before dilution with the main reaction solvent. Consistent particle sizing also plays a role, so batches with tighter sieving specifications exhibit dramatically improved wetting and dissolution rates.
Another issue revolves around the formation of byproducts during alkylation—especially the tendency for some nucleophiles to generate elimination byproducts under excess base. Our process team regularly shares detailed reaction protocols with downstream partners, promoting modified bases, optional potassium carbonate, and lower-temperature slow addition to suppress side reaction formation in these sensitive transformations.
We further invest in advanced analytical testing—routine in-process LC-MS and GC-FID methods track potential impurities, and custom stability studies allow chemists to confidently integrate our product into critical manufacturing campaigns. For multi-step processes, early detection of side-products or degradation intermediates reduces time and cost at later steps.
From daily practice, we recognize that trusted building blocks must meet more than minimum compendial requirements. Problems with off-spec batches, ambiguous certificates, or questionable traceability rightfully erode end-user confidence and project outcomes. We have built traceable process logs, every flask charge and lot of raw material cataloged, so if a customer runs up against unexpected analytical signals, rapid backtracking helps pinpoint the source. Our real-time consultation helps minimize downtime and maintain workflow continuity.
Our QC philosophy fights compositional drift—a problem when suppliers rely on intermediates that have sat too long in bulk storage. We rotate lots out regularly, use closed-system inert gas handling, and minimize transit time between purification and packaging. Moisture content, color, and residual solvent levels are measured at multiple process checkpoints.
The biggest quality differentiator: continuous operator training and a process environment focused on both safety and sustainability. Every production campaign integrates EHS assessments, so that environmental releases and worker exposure stay comfortably below regulatory thresholds. Our facility leverages closed-loop solvent recovery and real-time process analytics to keep both emissions and waste to a minimum.
Direct experience manufacturing this type of complex intermediate has taught us that open technical dialogue with end-users delivers tangible results. Chemists using 3-(Bromomethyl)-2-cyclopropyl-4-(4'-fluorophenyl)quinoline value prompt troubleshooting support, process guidance, and the ability to exchange performance data with the actual team producing the molecule. Rather than relying on abstract data sheets, we put practical, real-world experience into each customer discussion. This approach builds deeper partnerships, which in turn supports faster project advancement and greater confidence in using the material in regulated pharmaceutical pathways.
We’ve seen this compound deployed not only in mainstream medicinal chemistry, but also in specialty agrochemical analogues, photoreactive polymers, and new ligand design. In every context, feedback consistently points to the same advantages: batch consistency, robust performance under challenging reaction conditions, and reliable supply. Every advancement downstream reflects the care and technical rigor applied at each manufacturing stage.
Scaling up this molecule demands a clear-eyed approach to environmental stewardship. We minimize waste by regenerating brominating agents on-site and maximize product yield by designing workups with solvent exchange in mind. Whenever possible, we swap out petrochemical solvents for biobased alternatives, provided reaction selectivity still meets project needs. For every batch released, full origin and sustainability documentation travels with the shipment—customers downstream know exactly what went into production and how it reflects shared values of safety and accountability.
Staff in charge of daily production are trained not only in the chemistry, but also in emergency response, containment, and material compatibility. Handling and packaging involve frequent ergonomic reviews to reduce risk of repetitive strain, and automation handles any phase transfer operations that could otherwise pose a safety hazard. Compared to off-the-shelf, distributor-packed intermediates, this philosophy yields improved lot integrity and a safer workplace for all.
Having witnessed evolving structure-activity needs and the push for lower-impurity intermediates, our team views the next few years as pivotal for high-integrity synthetic building blocks. Chemists globally express growing demand for higher selectivity, faster scale-up, and more predictably pure materials. We continue to adapt upstream and downstream practices, whether that means new crystallization techniques, expanded impurity profiling, or closer production-partner ties. As medicinal and specialty chemistry expands its frontiers, trust in reliable starting points like this will only take on greater importance.
Being the manufacturer means taking personal responsibility for the quality, safety, and consistency of every lot. The expertise built over countless batches underpins not just the compound in the bottle, but also the relationships and innovations that grow from it. In every bottle of 3-(Bromomethyl)-2-cyclopropyl-4-(4'-fluorophenyl)quinoline, years of hands-on research, direct feedback from the development trenches, and the drive to constantly do better come together—advancing science, project by project.